A hyaluronic acid-based filler reduces lipolysis in human mature adipocytes and maintains adherence and lipid accumulation of long-term differentiated human preadipocytes.


Journal

Journal of cosmetic dermatology
ISSN: 1473-2165
Titre abrégé: J Cosmet Dermatol
Pays: England
ID NLM: 101130964

Informations de publication

Date de publication:
May 2021
Historique:
revised: 22 07 2020
received: 29 01 2020
accepted: 22 09 2020
pubmed: 6 11 2020
medline: 15 5 2021
entrez: 5 11 2020
Statut: ppublish

Résumé

The beneficial role of subcutaneous adipose tissue in skin rejuvenation derived from its capacity to fill the under-layer volumes but also from its ability to regulate the extracellular matrix production by dermis fibroblasts. Hyaluronic acid (HA), a major component of the extracellular matrix, is a commonly used injectable dermal filler showing excellent efficiencies to maintain tissue augmentation even after its biodegradation. To improve their stability, the HA molecules can also be "cross-linked" to each other. The effects of cross-linked HA-based fillers on the dermal structure are well known. For safety reasons, most of the physicians prefer to use the blunt cannula for injections. However, evidences showed that the cannula could not be located in the dermis, but it passes through immediate hypodermis and the long-lasting effect of cross-linked HA-based fillers may be related to its effects on adipose tissue. To test whether cross-linked HA has a direct effect on human adipocytes, we treated isolated adipocytes and precursors cells from human skin donors with cross-linked HA. Biochemical and cellular analysis demonstrated that treatment by cross-linked HA showed beneficial effects on differentiated cell adherence and survival as well as reduced basal and induced lipolysis in fully mature adipocytes. Taken together, these data showed that cross-linked HA promoted cell adherence and preserved the adipogenic capacity of preadipocytes during prolonged cell culture, bringing additional evidences of the beneficial role of cross-linked HA-based fillers in maintenance of the subcutaneous fat mass. This first study could defend a preventive approach to facial volume loss during natural aging.

Identifiants

pubmed: 33150734
doi: 10.1111/jocd.13794
pmc: PMC8246837
doi:

Substances chimiques

Dermal Fillers 0
Lipids 0
Hyaluronic Acid 9004-61-9

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1474-1482

Informations de copyright

© 2020 Laboratoires FILLMED. Journal of Cosmetic Dermatology published by Wiley Periodicals LLC.

Références

J Invest Dermatol. 2015 Sep;135(9):2331-2334
pubmed: 25880703
Aging Cell. 2010 Oct;9(5):667-84
pubmed: 20701600
Rev Prat. 1994 Sep 1;44(13 Suppl):29-32
pubmed: 8091109
Plast Reconstr Surg. 2018 Jul;142(1):112-121
pubmed: 29952893
BMC Oral Health. 2017 Jan 16;17(1):44
pubmed: 28093072
Adv Drug Deliv Rev. 2007 Nov 10;59(13):1351-65
pubmed: 17804111
Mol Endocrinol. 2009 Jan;23(1):11-24
pubmed: 18945811
Endocrinology. 2007 Feb;148(2):868-77
pubmed: 17082259
J Biol Chem. 2019 Jan 25;294(4):1083-1088
pubmed: 30563836
Stem Cell Rev Rep. 2012 Mar;8(1):55-66
pubmed: 21365256
Ciba Found Symp. 1989;143:187-201; discussion 201-7, 281-5
pubmed: 2478344
J Clin Endocrinol Metab. 2017 Mar 1;102(3):1032-1043
pubmed: 28359093
Biochimie. 2016 Jun;125:195-203
pubmed: 27060433
Blood. 2003 Feb 1;101(3):856-62
pubmed: 12393456
J Cosmet Dermatol. 2021 May;20(5):1474-1482
pubmed: 33150734
Carbohydr Res. 2005 Apr 11;340(5):791-809
pubmed: 15780246
Differentiation. 2007 Jun;75(5):360-70
pubmed: 17286602
Clin Plast Surg. 2005 Apr;32(2):151-62
pubmed: 15814113
Nutr Rev. 1999 Oct;57(10):324-6
pubmed: 10575910
FEBS Lett. 2007 Dec 11;581(29):5591-6
pubmed: 17997987
Biofactors. 2007;31(3-4):229-36
pubmed: 18997286
Med Hypotheses. 2015 Apr;84(4):327-30
pubmed: 25665858
Mol Med Rep. 2017 Oct;16(4):4095-4100
pubmed: 28731160
Biochem Biophys Res Commun. 2016 Sep 2;477(4):678-684
pubmed: 27349869
Aging (Albany NY). 2016 Jul;8(7):1457-69
pubmed: 27434510
Clin Interv Aging. 2017 Dec 06;12:2069-2076
pubmed: 29255352
Plast Reconstr Surg. 2001 Aug;108(2):411-20; discussion 421-2
pubmed: 11496183
Exp Dermatol. 2014 May;23(5):295-303
pubmed: 24628940
Future Lipidol. 2007 Apr;2(2):229-237
pubmed: 19194515
Dermatol Surg. 2018 Apr;44(4):549-556
pubmed: 29059139
Biomaterials. 2003 Aug;24(18):3125-32
pubmed: 12895585
PLoS One. 2017 Aug 10;12(8):e0182865
pubmed: 28797059
Cell Physiol Biochem. 2017;44(3):1078-1092
pubmed: 29179206
Stem Cells Dev. 2017 Nov 1;26(21):1578-1595
pubmed: 28874101
Biomaterials. 2008 Oct;29(29):3953-9
pubmed: 18635258

Auteurs

Karim Nadra (K)

Laboratoires FILL-MED, Paris, France.

Mathilde André (M)

D.I.V.A. Expertise, Toulouse, France.

Emmanuelle Marchaud (E)

D.I.V.A. Expertise, Toulouse, France.

Philippe Kestemont (P)

Mediti-Clinique Science et Beauté, Juan-les-Pins, France.

Frédéric Braccini (F)

Facial Plastic Surgery, HNS & FPS Riviera Institute, Nice, France.

Hugues Cartier (H)

Centre Medical Saint-Jean, Arras, France.

Mayoura Kéophiphath (M)

D.I.V.A. Expertise, Toulouse, France.

Ferial Fanian (F)

Laboratoires FILL-MED, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH